Background: Malignant pleural effusion is a commonly seen complication of malignancies such as lung and breast cancers. In Western countries, talc is frequently used as a standard therapeutic agent (pleurodesis agent) with the aim of alleviating symptoms including dyspnea and chest pain. Talc is not recognized as a pleurodesis agent in Japan. The aim of this study was to verify the efficacy and safety of sterilized talc (NPC-05) for the introduction of talc in Japan. Methods: The study was a single-arm, open-label, investigator-initiated trial conducted jointly at six institutions. The subjects were 30 patients with malignant pleural effusions. A solution of 4 g NPC-05 suspended in 50 ml physiological saline was instilled into the pleural space to perform pleurodesis. Results: The efficacy of NPC-05 for pleural adhesion 30 days after pleurodesis was 83.3% (25/30 cases). Amelioration of dyspnea and pain (chest pain) was seen. Commonly seen adverse effects were increased C-reactive protein (CRP) and fever. Nearly all adverse events were phenomena previously reported as adverse effects of talc. No acute respiratory distress syndrome (ARDS) or other serious side effects occurred. Conclusion: The efficacy and safety of NPC-05 for malignant pleural effusion in Japanese patients was verified, and the clinical outcomes with talc were confirmed to be the same as previously reported in other countries. There is thought to be a high level of need for this agent in the treatment of malignant pleural effusion in Japan.
Introduction
Malignant pleural effusion is commonly seen as a complication of malignancies such as lung and breast cancers. It is also a serious complication of malignant pleural mesothelioma associated with asbestos. Most malignant pleural effusion patients are in the terminal phase of cancer, with short anticipated survival. Increased malignant pleural effusion gives rise to dyspnea, chest pain, and other manifestations that markedly decrease patients' quality of life (QOL). In such cases adhesion of the pleura is done to prevent re-accumulation of malignant pleural effusion and control these symptoms. Such attempts to improve patient QOL are valuable as palliative treatment. In Western countries the pleural adhesion effect of talc, and its persistence, has been assessed positively in many randomized controlled trials, meta-analyses, and USA and UK guidelines. It is known as the standard therapeutic agent (pleurodesis agent) for malignant pleural effusion. In Japan, only OK-432 has been approved for use as a pleurodesis agent; however, treatment of malignant pleural effusion with OK-432 has a high incidence of fever and other adverse effects. It is not used in Western countries. The active ingredient of OK-432 is lyophilized hemolytic streptococcus, and there is also a risk of anaphylaxis from the added penicillin. In Western countries, talc is already frequently used as a standard therapeutic agent (pleurodesis agent) for malignant pleural effusion. Adverse effects such as ARDS are thought to occur at a low rate with sterilized talc of adjusted particle size, and this study was done with the aim of verifying the efficacy and safety of NPC-05 so that it can be introduced into Japan (1). This study was conducted with NPC-05, as an investigator-initiated clinical trial supported by a Ministry of Health, Labour and Welfare research grant.
Methods

Study design and patients
This study was conducted as a single-arm, open-label, investigatorinitiated trial at six institutions. The study was approved by the clinical review board at each institution, and conducted from June 2009 to March 2010, and registered in JMACCT (JMA-IIA00029). The targeted enrollment (NPC-05 administration) for the study was 30 patients with malignant pleural effusion. The effective rate in the main randomized controlled trials for talc (14 reports, 568 evaluable cases) was 71-100% (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . Presuming that the lowest effective rate of this investigational drug is 70% based on these results, the expected effective rate was set to 70%. On the other hand, referring to the results of other drugs (2-15), the threshold was set to 40%. In contrast to the null hypothesis that 'the true effective rate of the investigational drug is less than or equal to the threshold of 40%', the alternative hypothesis is that 'the true effective rate of this investigational drug is higher than the threshold of 40%'. The sample size required for the test using binomial distribution with the significance level of 2.5% and the detection power of 80% was calculated as 21. We set the sample size as 30 with the consideration of drop-out.
In this study, patients who satisfied the following criteria were included: (1) definitive diagnosis of carcinomatous pleurisy based on tissue diagnosis or cytodiagnosis; (2) breathing difficulty or other symptoms due to malignant pleural effusion, and control of it as a treatment priority; (3) sufficient lung re-expansion with drainage of pleural effusion through a thoracic drainage tube; (4) alleviation of breathing difficulty or other symptoms from drainage of pleural effusion; (5) expected survival of at least 30 days after the pleurodesis; (6) Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 after drainage of malignant pleural effusion; (7) age between 20 and 75 years; (8) written informed consent provided by the individual subjects for participation in the trial. Patients who satisfied the following criteria were excluded: (1) hypersensitivity to talc; (2) hypersensitivity to lidocaine hydrochloride; (3) concomitant serious infection; (4) advanced emphysema and/or fibrosis in the lungs; (5) current treatment for cardiac failure at the time of consent; (6) history of myocardial infarction within 30 days of consent; (7) advanced blood coagulation disorder; (8) SpO2 of less than 90% after pleural effusion drainage; (9) conspicuous pleural adhesions; (10) bilateral pleural adhesion thought to be needed; (11) history of intrapleural surgical procedures, such as lung resection or extrapleural pneumonectomy, on the affected side; (12) history of pleurodesis on the affected side; (13) treatment with systemic administration (oral or intravenous) of corticosteroids at the time of consent; (14) current pregnancy or lactation, or hope of becoming pregnant or inability to take appropriate contraceptive measures during the study period; (15) participation in a different trial within 6 months of providing consent; (16) determination by principal investigator or sub-investigator that participation in this study is inappropriate.
Material
NPC-05 was a preparation filled with 4 g of sterilized talc (sterilized controlled talc) whose particle size was adjusted in one vial, and was provided free of charge from Nobel Pharma Corporation. In addition, NPC-05 has been approved domestically in 2013 and is on the market (product name: Unitalc ® ).
Pleurodesis
A 16F-24F double lumen thoracic drainage tube was placed in the pleural cavity. Drainage was done at a target rate of less than 1000 ml per day; if the drainage amount exceeded 1000 ml, drainage was done over 2 or more days. The pleural effusion was drained as much as possible, and re-expansion of the lung and amelioration of dyspnea or other symptoms was confirmed on chest radiograph (CXR) after drainage. To suppress pain (chest pain), 10 ml of 1% lidocaine hydrochloride was instilled into the pleural space, followed by a solution of NPC-05 suspended in 50 ml of physiological saline. This was followed by additional instillation of 50 ml physiological saline (wash), and clamping of the drainage tube for 2 h. The patient's body position was changed every 15 min within the range of possible postures so that the NPC-05 suspension would reach all parts of the pleural space. The drainage fluid was continuously aspirated with negative pressure using a continuous suction unit at low pressure (target: −10 cmH 2 O), and the tube was removed when the amount of drainage fell below 150 ml per day. In cases when the amount of drainage had not decreased to below 150 ml by 7 days postoperatively, the treatment was considered to be ineffective and it was discontinued. Concurrent use of OK-432, antineoplastic agents, and corticosteroids was prohibited. Use of antineoplastic agents was prohibited from the time of consent until 7 days after pleurodesis. These agents could then be used in systemic chemotherapy but intrapleural administration was prohibited until 30 days after pleurodesis. Use of corticosteroids was prohibited from the time of consent until removal of the drainage tube after pleurodesis. External use was allowed.
Outcome measures (1) Efficacy evaluation
The primary endpoint was 'presence or absence of re-accumulation of pleural effusion 30 days after pleurodesis,' determined by a third-party efficacy assessment committee. The presence or absence of reaccumulation of pleural effusion was compared on chest radiographs (CXR) immediately after drain removal and 30 days after pleurodesis. The criteria were as follows. Effective: No re-accumulation of pleural effusion seen (accumulation of <10% in the hemithorax immediately after extubation).
Ineffective: Re-accumulation of pleural effusion seen, and symptoms present. Cases with no symptoms even though re-accumulation of pleural effusion of ≥10% was seen in the hemithorax immediately after extubation were assessed as 'partially effective.' These cases were not treated as effective cases. The efficacy rate was calculated as: (no. of cases evaluated as 'effective')/(no. of cases for the efficacy analysis).
Secondary endpoints were 'severity of dyspnea 30 days after pleurodesis' and 'severity of pain (chest pain) 30 days after pleurodesis.' For severity of dyspnea, the severity (grade) of dyspnea before pleural drainage and at 30 days after pleurodesis or discontinuation was compared. For the severity of pain (chest pain), the grade of pain before pleural drainage and 30 days after pleural drainage or discontinuation was compared. The grade of dyspnea was determined as follows (4) 
Statistical analysis
The patient population for efficacy analysis consisted of a full analysis set, which was defined as a set of subjects dosed with NPC-05. The safety analysis set for statistical evaluation comprised all patients who were administered NPC-05. Precise interval estimation based on binomial distribution was used in interval estimates of the efficacy rate. For the efficacy rate, the null hypothesis that 'the true efficacy rate was below the threshold efficacy rate (40%) at which the treatment was judged to be ineffective,' was tested using a precise test according to a binomial distribution based on the observed efficacy rate. For the severity of dyspnea and the severity of pain (chest pain), the changes in the respective severities before and after were compared with the Wilcoxon signed rank test.
Results
Patients
Thirty patients were registered as eligible for the analysis, and NPC-05 was administered to all of them. The treatment was discontinued in a total of four cases, one because of use of a prohibited agent (corticosteroid), one because of occurrence of an adverse event (infection at the drain insertion site 5 days after administration of NPC-05, and skin infection that led to empyema), and two because of insufficient effect. The number of study completion of subjects was then 26. Patient characteristics are shown in Table 1 . Mean age was 61.0 years (31-75 years). There were 22 men and eight women. The underlying disease was lung cancer in 76.7% (23/30 patients) and breast cancer in 6.7% (2/30 patients). Other cases were one each of palate cancer, stomach cancer, kidney cancer, malignant lymphoma and malignant pleural mesothelioma.
Efficacy
The efficacy evaluation was done with all 30 patients who received NPC-05.
(1) Primary endpoint The pleural adhesion effect of NPC-05, indicated by presence or absence of re-accumulation of pleural effusion at 30 days after pleurodesis or the time of discontinuation, is shown in Table 2 . Of the three cases judged as 'ineffective' in Table 2 , two cases showed pleural effluent volume of 150 ml/day or more at 7 days after pleurodesis, so it was judged as ineffective according to the protocol. One case was judged as ineffective because re-accumulation of pleural effusion was observed at 30 days after pleurodesis. The efficacy rate of NPC-05 in inhibiting re-accumulation of pleural effusion, judged by the 'presence or absence of re-accumulation of pleural effusion at 30 days after pleurodesis (or the time of discontinuation),' was 83.3% (25/30 patients, 95% CI 0.653-0.944). The efficacy rate thus showed sufficiently high significance (P < 0.001). NPC-05 was clearly demonstrated to inhibit re-accumulation of pleural effusion. Tables 3 and 4 show the severity of dyspnea and pain (chest pain) (VAS), respectively, before and after pleurodesis. Compared with before the start of pleural effusion drainage, a significant improvement was seen in the severity (grade) of dyspnea after administration of NPC-05 (P < 0.001). The mean (±SD) severity (VAS) of pain (chest pain) before the start of pleural effusion drainage and 30 days after pleurodesis (or at time of discontinuation) was 20.8 ± 23.9 and 14.3 ± 24.7, respectively. Compared with before the start of pleural effusion drainage, a significant improvement was seen in pain (chest pain) after administration of NPC-05 (P = 0.022).
(2) Secondary endpoints
(3) Persistence of effect
The adhesive effect of pleurodesis, and the persistence of that effect, strongly affects the subsequent re-accumulation of pleural effusion. Data are n (%) or mean ± SD (range) Therefore, as a clinical study by the institutions participating in this study, efficacy evaluations were done at 60 and 90 days after pleurodesis in the participating patients, respectively. The subjects were 25 patients from whom consent to participate in this clinical investigation was obtained. The long-term efficacy against malignant pleural effusion following pleurodesis with NPC-05 was surveyed in these patients. The results of evaluations of the presence or absence of re-accumulation of pleural effusion based on CXR showed efficacy rates for NPC-05 of 83.3% (20/24) and 77.3% (17/22) at 60 and 90 days after pleurodesis, respectively. Persistence was demonstrated in the pleural adhesion effect of NPC-05.
Safety
Safety was evaluated in all 30 patients who received NPC-05. There was no ARDS or other serious adverse reactions. There were also no serious adverse effects seen in a survey of long-term safety (serious adverse effects) 60 and 90 days after pleurodesis. The grade-based tabulation of adverse effects is shown in Table 5 . Frequently seen adverse effects were increased CRP in 80% (24/30 patients) and fever in 53.3% (16/30) . These events occurred especially during days 1-7 after administration of NPC-05, with respective incidences of 73.3% (22/30 patients) and 53.3% (16/30 patients). The severity of adverse effects was advanced in a total of three cases, one patient with both dyspnea and cancer pain, one patient with increased ALT, and one patient with increased serum potassium. There is no lifethreatening Grade 4 by severity, Grade 3 is 10% (3/30 cases), Grade 2 46.7% (14/30 cases), Grade 1 was recognized at 90% (27/30 cases). Body temperature was significantly increased from the prepleural effusion drainage level (36.6 ± 0.4°C) on post-pleurodesis Day 1 only (37.0 ± 0.8°C). There were no significant differences after that. Fever was expressed temporarily immediately after pleurodesis.
Discussion
The method of evaluating efficacy in this study was objective and similar to methods used in foreign trials. Since it is possible to compare the outcomes in this study and studies from other countries, it was thought that the efficacy and safety of NPC-05 could be confirmed in a single-arm, open-label clinical trial. This trial investigated the efficacy and safety of NPC-05 pleurodesis for malignant pleural effusion. This study used sterilized talc in which the particle size was adjusted to exclude small particles. These small particles are thought to be a cause of ARDS (16) (17) (18) (19) , the adverse effect of greatest concern with talc. From the outcomes of many previous clinical trials, a low amount of 4 g of talc was established. This is thought to be an amount with which a consistent efficacy can be expected, and also to be safer. The main method of evaluating efficacy adopted in this study was objective determination of the presence or absence of re-accumulation of pleural effusion on CXR by third-party evaluators, who are not biased. This study is the first in Japan to be conducted for the introduction of talc as a standard therapeutic agent in Japan. As shown in Table 6 , the efficacy seen in this study (83.3%) is comparable to that in many previous reports (efficacy of talc slurry in major randomized trials: 71-100%). NPC-05 was confirmed to be effective in pleurodesis for malignant pleural effusion. Persistence in the pleural adhesion effect of NPC-05 was also seen. Since an anticipated efficacy similar to previous reports was obtained, the usage, dosage and evaluation method in this study Precise interval estimation based on binomial distribution was used in the efficacy rate. Binominal test was submitted under the null hypothesis that the true efficacy rate was below the threshold efficacy rate of 40%. are thought to be valid. Increased CRP, an inflammatory marker expressed with a high frequency, and fever were seen in the early period after administration of NPC-05. These phenomena are thought to be associated with the elicitation of inflammation by expression of the pleural adhesive effect of NPC-05. The severity of fever was Grade 1 in 36.7% of cases (11/30 patients) and Grade 2 in 16.7% (5/30 patients). There were no cases of high fever. Therefore, control of fever is thought to be possible with antipyretics. When pleurodesis using talc is performed for intractable hepatic hydrothorax, hepatic dysfunction (elevated alanine aminotransferase (ALT)) is seen. The mechanism of the effects of talc on the liver is unknown, but the possibility is reported that talc is related to the onset of hepatocellular damage via the inflammatory factors that are produced in large amounts when talc induces aseptic inflammation (24) . Further attention to the effects of NPC-05 on liver function will be needed. No ARDS was seen in this study and there were no serious side effects. There were also no deaths during the 30-day study period; thus, the selection of patients for the study was thought to be appropriate. NPC-05 is sterilized talc with particle size adjusted to exclude small particles. With this and the small administered dose of 4 g it is thought that ARDS can be mostly avoided (22, (25) (26) (27) , but it will be important to observe this with close attention in the future. Among outcomes reported in detail from randomized controlled studies conducted in Japan, frequently expressed adverse effects of OK-432 are fever, chest pain, ALT abnormalities and aspartate transaminase (AST) abnormalities, with respective incidences of 78.1% (25/32), 75% (24/32), 65.6% (21/ 32) and 53.1% (17/32) (28). Although not a direct comparison, these adverse effects all occurred at a lower rate in the present study than in the above. From this it is conjectured that NPC-05 may be superior to OK-432 in terms of safety. In Japan there are reports of three cases in which ARDS occurred (29, 30) when Steritalc was Including one case of Grade 3 out of two cases of dyspnea (6.7%) not described in the table because of the incidence of less than 10%. used in young people. One factor in this is thought to be that these patients started with poor status and low respiratory reserve. In the present study the procedure was performed in patients with good performance status and ARDS was seen in only one patient. Sufficient caution should be exercised when administering NPC-05 to patients with poor performance status. The efficacy and safety of NPC-05 was verified in this study. The efficacy was comparable to previous reports of talc efficacy, and the adverse effects were in a range that could be predicted from previously reported talc adverse effects. Thus, it is thought that NPC-05 can be used safely. Talc is known to be a standard therapeutic agent (pleurodesis agent) for malignant pleural effusion in Western countries. NPC-05 may become a standard therapeutic agent for malignant pleural effusion in place of OK-432 in Japan.
